Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

63°
- Benton, AR (72018)
  Today
  
  Partly cloudy. High 83F. Winds S at 5 to 10 mph..
  
  Tonight
  
  Generally clear skies. Low 57F. Winds light and variable.
  
  Updated: April 10, 2026 @ 8:56 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

92.92 +0.94 (+1.03%)

Streaming Delayed Price Updated: 10:49 AM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

March 24, 2026

From BioNTech SE

Via GlobeNewswire

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗

March 10, 2026

Via Chartmill

Why BioNTech Stock Is Getting Crushed Today ↗

March 10, 2026

Nothing about the recent past, present, or foreseeable future seems all that compelling.

Via The Motley Fool

Gapping stocks in Tuesday's session ↗

March 10, 2026

Via Chartmill

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗

January 16, 2026

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

March 10, 2026

Via Chartmill

Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗

March 10, 2026

BioNTech co-founders Ugur Sahin and Özlem Türeci are set to leave the company to head the new venture.

Via Stocktwits

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

March 10, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

March 10, 2026

From BioNTech SE

Via GlobeNewswire

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

February 24, 2026

From BioNTech SE

Via GlobeNewswire

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology

February 11, 2026

Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Intellectual Property

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

January 28, 2026

From BioNTech SE

Via GlobeNewswire

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

They could perhaps see sustained runs beyond this year.

Via The Motley Fool

Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally

January 22, 2026

In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for...

Via MarketMinute

Topics Intellectual Property

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

January 14, 2026

Issued on behalf of Oncolytics Biotech Inc.

From USA News Group

Via GlobeNewswire

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗

January 14, 2026

Via Chartmill

Topics Government

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From BioNTech SE

Via GlobeNewswire

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

BioNTech SE - American Depositary Shares (NQ:BNTX)

All News about BioNTech SE - American Depositary Shares

Sections

Services

Follow Us